Metabolic activation of polycyclic aromatic hydrocarbons and aryl and heterocyclic amines by human cytochromes P450 2A13 and 2A6.

Human cytochrome P450 (P450) 2A13 was found to interact with several polycyclic aromatic hydrocarbons (PAHs) to produce Type I binding spectra, including acenaphthene, acenaphthylene, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, and 1-nitropyrene. P450 2A6 also interacted with acenaphthene and acenaphthylene, but not with fluoranthene, fluoranthene-2,3-diol, or 1-nitropyrene. P450 1B1 is well-known to oxidize many carcinogenic PAHs, and we found that several PAHs (i.e., 7,12-dimethylbenz[a]anthracene, 7,12-dimethylbenz[a]anthracene-5,6-diol, benzo[c]phenanthrene, fluoranthene, fluoranthene-2,3-diol, 5-methylchrysene, benz[a]pyrene-4,5-diol, benzo[a]pyrene-7,8-diol, 1-nitropyrene, 2-aminoanthracene, 2-aminofluorene, and 2-acetylaminofluorene) interacted with P450 1B1, producing Reverse Type I binding spectra. Metabolic activation of PAHs and aryl- and heterocyclic amines to genotoxic products was examined in Salmonella typhimurium NM2009, and we found that P450 2A13 and 2A6 (as well as P450 1B1) were able to activate several of these procarcinogens. The former two enzymes were particularly active in catalyzing 2-aminofluorene and 2-aminoanthracene activation, and molecular docking simulations supported the results with these procarcinogens, in terms of binding in the active sites of P450 2A13 and 2A6. These results suggest that P450 2A enzymes, as well as P450 Family 1 enzymes including P450 1B1, are major enzymes involved in activating PAHs and aryl- and heterocyclic amines, as well as tobacco-related nitrosamines.

[1]  G. Lushington,et al.  Key Residues Controlling Binding of Diverse Ligands to Human Cytochrome P450 2A Enzymes , 2009, Drug Metabolism and Disposition.

[2]  S. Dehal,et al.  HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 , 2006, Drug Metabolism and Disposition.

[3]  M. Ingelman-Sundberg,et al.  Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment , 2009, Human Genetics.

[4]  G. Wogan,et al.  Formation and persistence of DNA adducts in organs of CD-1 mice treated with a tumorigenic dose of fluoranthene. , 1995, Carcinogenesis.

[5]  T. Tan,et al.  Curcumin inhibited the arylamines N-acetyltransferase activity, gene expression and DNA adduct formation in human lung cancer cells (A549). , 2003, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  G. Miller,et al.  Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. , 2000, Biochemistry.

[7]  F. Guengerich,et al.  Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. , 1993, Archives of biochemistry and biophysics.

[8]  H. Yamazaki,et al.  Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds. , 2011, Chemical research in toxicology.

[9]  T. Shimada,et al.  Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. , 2006, Chemical research in toxicology.

[10]  H. Yamazaki,et al.  O I.4 Roles of human cytochrome P450s 1A1, 1A2, 1B1, 2E1, and 3A4/5/7 in the activation of environmental procarcinogens and promutagens , 1997 .

[11]  F. Guengerich.  Oxidation-reduction properties of rat liver cytochromes P-450 and NADPH-cytochrome p-450 reductase related to catalysis in reconstituted systems. , 1983, Biochemistry.

[12]  Eric F. Johnson,et al.  Structural Characterization of the Complex between α-Naphthoflavone and Human Cytochrome P450 1B1* , 2010, The Journal of Biological Chemistry.

[13]  Huai-chih Chiang,et al.  Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach. , 2011, Toxicology and applied pharmacology.

[14]  E. Scott,et al.  Nicotine and 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Binding and Access Channel in Human Cytochrome P450 2A6 and 2A13 Enzymes* , 2012, The Journal of Biological Chemistry.

[15]  H. Yamazaki,et al.  Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  P. Rudnai,et al.  Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen-DNA adducts. , 2007, Mutagenesis.

[17]  N. Tretyakova,et al.  Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.

[18]  S. Amin,et al.  Mammary carcinogenicity in female CD rats of a diol epoxide metabolite of fluoranthene, a commonly occurring environmental pollutant. , 1995, Carcinogenesis.

[19]  F. Guengerich,et al.  Analysis of Coumarin 7-Hydroxylation Activity of Cytochrome P450 2A6 using Random Mutagenesis* , 2005, Journal of Biological Chemistry.

[20]  R. Tukey,et al.  Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. , 1994, Archives of biochemistry and biophysics.

[21]  H. Yamazaki,et al.  Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition. , 2013, Chemical research in toxicology.

[22]  F. Guengerich,et al.  Drug metabolism by Escherichia coli expressing human cytochromes P450 , 1997, Nature Biotechnology.

[23]  S. Hecht,et al.  Synthesis of stereospecifically deuterated 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) iastereomers and metabolism by A/J mouse lung microsomes and cytochrome p450 2A5. , 2003, Chemical research in toxicology.

[24]  Huai-chih Chiang,et al.  Differential Distribution of CYP2A6 and CYP2A13 in the Human Respiratory Tract , 2012, Respiration.

[25]  W. Pryor.  Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .

[26]  Hiroshi Yamazaki,et al.  Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. , 2008, Chemical research in toxicology.

[27]  F. Guengerich,et al.  Analysis and Characterization of Enzymes and Nucleic Acids , 2007 .

[28]  W. Busby,et al.  Induction of lung and liver tumors by fluoranthene in a preweanling CD-1 mouse bioassay. , 1993, Carcinogenesis.

[29]  S. Besley,et al.  Sensitive Method for the Detection of Experimental Brain Lesions , 1973, Perceptual and motor skills.

[30]  S. Hecht,et al.  Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine. , 2005, Chemical research in toxicology.

[31]  K. Rajagopalan,et al.  from Human Liver , 1976 .

[32]  Hiroshi Yamazaki,et al.  Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. , 2009, Chemical research in toxicology.

[33]  S. Amin,et al.  Tumorigenicity in newborn mice of fjord region and other sterically hindered diol epoxides of benzo[g]chrysene, dibenzo[a,l]pyrene (dibenzo[def,p]chrysene), 4H-cyclopenta[def]chrysene and fluoranthene. , 1995, Carcinogenesis.

[34]  S. Anttila,et al.  Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis. , 2011, American journal of respiratory cell and molecular biology.

[35]  Shu-Feng Zhou,et al.  Structure, function, regulation and polymorphism of human cytochrome P450 2A6. , 2009, Current drug metabolism.

[36]  G. Wogan,et al.  Tumorigenicity of fluoranthene in a newborn mouse lung adenoma bioassay. , 1984, Carcinogenesis.

[37]  D. Parke,et al.  The cytochromes P450 and mechanisms of chemical carcinogenesis. , 1994, Environmental health perspectives.

[38]  E. LaVoie,et al.  Tumorigenic activity of fluoranthene, 2-methylfluoranthene and 3-methylfluoranthene in newborn CD-1 mice. , 1994, Carcinogenesis.

[39]  A. Sparreboom,et al.  Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention , 2006, Molecular Cancer Research.

[40]  C. Stout,et al.  Structure of the Human Lung Cytochrome P450 2A13* , 2007, Journal of Biological Chemistry.

[41]  R. Estabrook,et al.  Spectral studies of drug interaction with hepatic microsomal cytochrome. , 1967, Molecular pharmacology.

[42]  Y. Hsueh,et al.  4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes gene polymorphisms, NNK metabolites levels and urothelial carcinoma. , 2013, Toxicology letters.

[43]  Jun-yan Hong,et al.  CYP2A13 in Human Respiratory Tissues and Lung Cancers: An Immunohistochemical Study with A New Peptide-Specific Antibody , 2006, Drug Metabolism and Disposition.

[44]  Jun-yan Hong,et al.  METABOLISM OF NICOTINE AND COTININE BY HUMAN CYTOCHROME P450 2A13 , 2005, Drug Metabolism and Disposition.

[45]  Jun-yan Hong,et al.  Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2000, Cancer research.

[46]  H. Shinagawa,et al.  Evaluation of the new system (umu-test) for the detection of environmental mutagens and carcinogens. , 1985, Mutation research.

[47]  Xinxin Ding,et al.  Transcriptional Regulation of Human CYP2A13 Expression in the Respiratory Tract by CCAAT/Enhancer Binding Protein and Epigenetic Modulation , 2007, Molecular Pharmacology.

[48]  C David Stout,et al.  Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen , 2005, Nature Structural &Molecular Biology.

[49]  L. Loeb,et al.  Environmental and chemical carcinogenesis. , 2004, Seminars in cancer biology.

[50]  K. Kanki,et al.  Lung as a new target in rats of 2‐amino‐3‐methylimidazo[4,5‐f]quinoline carcinogenesis: Results of a two‐stage model initiated with N‐bis(2‐hydroxypropyl)nitrosamine , 2006, Cancer science.

[51]  H. Bolt,et al.  Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1 , 2005, Expert opinion on drug metabolism & toxicology.

[52]  H. Yamazaki,et al.  Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. , 2007, Chemical research in toxicology.

[53]  大垣 比呂子.  Carcinogenicity in mice of a mutagenic compound, 2-amino-3-methylimidazo[4,5-f]quinoline, from broiled sardine, cooked beef and beef extract , 1986 .

[54]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[55]  R. Brown,et al.  Protein measurement using bicinchoninic acid: elimination of interfering substances. , 1989, Analytical biochemistry.

[56]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[57]  Stephen S Hecht,et al.  Lung carcinogenesis by tobacco smoke , 2012, International journal of cancer.

[58]  S. Murphy,et al.  Functional characterization of CYP2A13 polymorphisms. , 2007, Xenobiotica; the fate of foreign compounds in biological systems.